Background: Every drug has the potentiality to cause an adverse drug reaction (ADR). ADRs are a major problem in drug therapy. The aim of this study was to assess the incidence and causality, severity and Preventability of ADRs Amlodipine (antihypertensive agents) used for the essential hypertensive patients during the time period of April 2022 to Jun 2022. Methods: This prospective-observational study was carried out in general medicine outpatient department in 15 Patients. Results: Out of 15 patients, 10 (66.66%) patients were developed ADRs to antihypertensive drugs. 8 (85.72%) were male and 2 (14.28%) were female. Calcium channel blockers were the commonest therapeutic class of antihypertensive drugs associated with ADRS (n = 50, 64.10%). According to WHO causality assessment scale most of the ADRs of Amlodipine were "probable" 8(57.14%) followed by "possible" 2 (14.28%), certain 4 (28.57%)). According to Hartwig and Siegel scale of severity assessment, the most of the adrs were mild 10(71.42%) and moderate 4 (28.57%). According to Schumock and Thornton scale of preventability assessment all ADR are definitely preventable.
Conclusions: The results of this study concluded that antihypertensive drugs able to induce the development of adverse drug reactions, which were significant cause of increase burden on health care system and decrease the quality of life, the health care professionals should take care about the rational use of antihypertensive agents. Thus, to minimize the incidence of adverse drug reaction and to increase the quality of life.
Cite this article:
Akanksha K. Mane, V.J. Chaware. To Assess Causality, Severity and Preventability of Adverse drug reactions of Amlodipine in the treatment of hypertension. Asian Journal of Research in Chemistry. 2023; 16(1):39-2. doi: 10.52711/0974-4150.2023.00007
Akanksha K. Mane, V.J. Chaware. To Assess Causality, Severity and Preventability of Adverse drug reactions of Amlodipine in the treatment of hypertension. Asian Journal of Research in Chemistry. 2023; 16(1):39-2. doi: 10.52711/0974-4150.2023.00007 Available on: https://www.ajrconline.org/AbstractView.aspx?PID=2023-16-1-7
1. Safety of medicines in public health programmers. Pharmacovigilance an essential tool. Geneva WHO. 2006. Available at: https://www.who.int/medicines/areas/quality_safety/s afety efficacy/Pharmacovigilance_B.pdf. Accessed 10 January 2019.
2. 10 January 2019. Vora MB, Trivedi HR, Shah BK, Tripathi CB. Adverse drug reactions in inpatients of internal medicine wards at a tertiary care hospital: A prospective cohort study. J Pharmacol pharmacotherapies 2011; 2(1):21-5
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies.JAMA.1998; 279(15):1200-5.
4. Alomar MJ. Factors affecting the development of adverse drug reactions. 2014; 22(2):83-94. Saudi Pharmaceut J.
5. Beijer HJ, De Blaey CJ. Hospitalizations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy World Sci. 2002:24(2):46-54
6. Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary teaching Hospital. Pharmacol Res.care 2006; 54(3):226-33.
7. Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley and Sons, Ltd-2000:151-174.
8. de Araujo Lobo MG, Pinheiro SM, Castro JG, Momenté VG, Pramchevicius MC. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Toxicol. 2013 Dec; 14(1):5.
9. Patidar D, Rajput MS, Nirmal NP, Savitri W. Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdisciplinary Toxicol. 2013 Mar 1; 6(1):41-6
10. Srivastava M, Uchit G, Chakravarti A, Joshi G, Mahatme M, Chaudhari H. Adverse drug reactions reported in Indira Gandhi government medical college and hospital, Nagpur. J Assoc PhyPhysician.
11. World Health Organization (WHO). International drug monitoring: the role of national centers. Technical report no. 498, 1972, http://www.who umc.org/graphics/24756.pdf
12. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259. [PubMed] [Google Scholar].